ATLASPfizer (PFE) Q3 2026 earnings results
Pfizer (PFE) reported EPS of $0.87 against an analyst estimate of $0.72: a beat of $0.15 (20.8%). The quarter ended Sep 30, 2026; the company reported on Tuesday, November 3, 2026, before the open.
Status: Confirmed · 14:42 ET, Nov 3 · Source: EODHD (calendar and fundamentals, cross-checked)
Get an email before and after Pfizer reports, free with your ATLAS account
Earnings alerts are a free benefit of your ATLAS account. The company goes to your watchlist and we email you when it reports. Google signup is one click.
Create free accountPFE Q3 2026 results at a glance
| EPS reported | $0.87 |
|---|---|
| EPS estimate | $0.72 |
| Surprise | Beat · +$0.15 (+20.8%) |
| Quarter ended | Sep 30, 2026 |
| Reported | Nov 3, 2026, before the open |
| Status | Confirmed · 14:42 ET, Nov 3 |
EPS is as supplied by EODHD, in US dollars per share; whether it is adjusted or GAAP follows that source. This is Pfizer’s Q3 2026, a calendar-year company.
Pfizer EPS surprise history: last 5 quarters
Pfizer beat the EPS estimate in 5 of its last 5 reports, with an average surprise of +18.4%.
| Report date | EPS est. | EPS actual | Surprise | Result | Move* |
|---|---|---|---|---|---|
| Nov 3, 2026 | $0.72 | $0.87 | +20.8% | Beat | – |
| Aug 4, 2026 | $0.68 | $0.77 | +13.2% | Beat | +3.1% |
| May 5, 2026 | $0.72 | $0.75 | +4.2% | Beat | +0.9% |
| Feb 3, 2026 | $0.57 | $0.66 | +15.8% | Beat | +0.5% |
| Nov 4, 2025 | $0.63 | $0.87 | +38.1% | Beat | -0.2% |
*Move: change in the closing price from the last close before the report day to the close the day after it. It is filled in a few trading days after each report.
PFE stock reaction to the report
PFE moved -2.25% in the first session that reflects the report (close of Nov 2, 2026 $30.67 to close of Nov 3, 2026 $29.98).
Next PFE earnings report
Pfizer has not announced its next earnings date yet. This page shows a date only once it is confirmed. See the PFE earnings calendar.
ATLAS fair value and signal for PFE
| Last price | $30.56 (-0.4%) |
|---|---|
| ATLAS fair value | $36.78 (range $28.69–$67.48) · price is 17% below it |
| Chance of a higher close in 1 month | 53% (normal range $29.57–$31.83) |
These are model outputs from the same valuation and calibrated model as the Pfizer stock page. They describe an ordinary period and are not a forecast of any particular outcome.
Pfizer Q3 2026 earnings: frequently asked questions
Did Pfizer beat earnings estimates for Q3 2026?
Pfizer reported EPS of $0.87 against an analyst estimate of $0.72: a beat of $0.15 (20.8%).
When did Pfizer report Q3 2026 results?
Pfizer reported on Tuesday, November 3, 2026, before the open, for the quarter ended Wednesday, September 30, 2026.
How often does PFE beat EPS estimates?
In its last 5 reports with a recorded result, Pfizer beat the EPS estimate 5 times; the average surprise was +18.4%. Past results do not predict the next one.
How does ATLAS confirm a result?
A result is published only after it is cross-checked: the EODHD earnings calendar and the EODHD fundamentals feed must show the same EPS for the same fiscal period, or the same value must appear in two consecutive checks. Unconfirmed figures are never published. If the figures are revised later, this page updates.
Educational information, not investment advice. Disclaimer